Evidence map›Paper›PMID 24081940›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2013

Randomized trial to assess the impact of venlafaxine and soy protein on hot flashes and quality of life in men with prostate cancer.

Mara Z Vitolins, Leah Griffin, W Vic Tomlinson, Jacqueline Vuky, Paul T Adams, Dawn Moose, Bart Frizzell, Glenn J Lesser, Michelle Naughton, James E Radford and 1 more

Open access · bronzeAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 5 pooled it
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The effectiveness of lifestyle interventions to reduce side effects of androgen deprivation therapy for men with prostate cancer: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2020
    Pooled it
  4. Antidepressants for the treatment of depression in people with cancer.The Cochrane database of systematic reviews · 2018
    Pooled it
  5. Pooled it
  6. Trial
  7. Western Dietary Pattern, Prudent Dietary Pattern, and Cancer-Specific Quality of Life in Prostate Cancer Survivors in the Health Professionals Follow-Up Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  8. [Integration of complementary medicine in uro-oncology].Urologie (Heidelberg, Germany) · 2025
    Review
  9. Review
  10. A hospital-based therapeutic food pantry study for people living with cancer in New Orleans.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  11. Article
  12. Antidepressants for the treatment of depression in people with cancer.The Cochrane database of systematic reviews · 2023
    Review
  13. Review
  14. Top ten errors of statistical analysis in observational studies for cancer research.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018
    Review
  15. Review
  16. Article
  17. Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017
    Review
  18. Radiotherapy for high-risk prostate cancer.Nature reviews. Urology · 2015
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Mara Z VitolinsMara Z. Vitolins, Leah Griffin, Bart Frizzel, Glenn J. Lesser, Michelle Naughton, and Edward G. Shaw, Wake Forest School of Medicine; Dawn Moose, Novant Health, Winston-Salem; James E. Radford Jr, Hendersonville Hematology/Oncology, Hendersonville, NC; W. Vic Tomlinson, AnMed Health, Anderson, SC; Jacqueline Vuky, Virginia Mason Medical Center, Seattle, WA; and Paul T. Adams, National Surgical Adjuvant Breast and Bowel Project, Genesys Regional Medical Center, Flint, MI.
Leah Griffin
W Vic Tomlinson
Jacqueline Vuky
Paul T Adams
Dawn Moose
Bart Frizzell
Glenn J Lesser
Michelle Naughton
James E Radford
Edward G Shaw
Novant Health · USVirginia Mason Medical Center · US

Funding

Tumor Tissue CoreP30CA012197 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Ruben A. Mesa · 1985 to 2026
$55.4M
Comprehensive Cancer Center of Wake Forest University CCOP Research BaseU10CA081851 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SHAW, EDWARD G · 1999 to 2013
$22.0M
NCI NIH HHS P30 CA012197NCI NIH HHS U10 CA081851NCI NIH HHS U10 CA 081851-06S2NCI NIH HHS U10 CA081851-06S2
6 · The paper itself

Abstract

purposeHot flashes occur in approximately 80% of androgen-deprived men. Few intervention studies have been conducted to relieve hot flashes in men. PATIENTS AND

methodsEligible androgen-deprived men were randomly assigned to one of four daily regimens (2 × 2 factorial design) for 12 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder and placebo pill, or venlafaxine and soy protein powder. The primary end point was hot flash symptom severity score (HFSSS), defined as number of hot flashes times severity. The secondary end point was quality of life (QoL), assessed by using the Functional Assessment of Cancer Therapy-Prostate.

resultsIn all, 120 men age 46 to 91 years participated. Most were white (78%) and overweight or obese (83%). Toxicity was minimal. Neither venlafaxine nor soy protein alone or in combination had a significant effect on HFSSS. Soy protein, but not venlafaxine, improved measures of QoL.

conclusionIn androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot flashes. Interventions that appear effective for decreasing hot flashes in women may not always turn out to be effective in men.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsCyclohexanolsDouble-Blind MethodHot FlashesHumansMaleMiddle AgedProstatic NeoplasmsQuality of LifeSelective Serotonin Reuptake InhibitorsSoybean ProteinsVenlafaxine HydrochlorideAndrogen AntagonistsCyclohexanolsSelective Serotonin Reuptake InhibitorsSoybean ProteinsVenlafaxine Hydrochloride

Identifiers

PMID24081940
PMCPMC3816959
OpenAlexW2158681327

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.